A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma

Completed · Early Phase 1

Conditions studied: Mesothelioma

In brief

The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant to enhance the efficacy Keytruda

Key facts

Study ID

NCT04056026

Run by

ProgenaBiome

People needed

1

Starts

2018-09-18

Expected to finish

2018-12-18

Last updated by the study team

2019-09-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with metastatic mesothelioma deemed a candidate for PD-1 blockade inhibitor therapy

You may not qualify if…

• Patient unable/unwilling to comply with protocol
• Patient deemed not a candidate for PD-1 Blockade inhibitor therapy

Where it is running

• ProgenaBiome — Ventura, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.